CanSino Biologics and Jiankai Technology have a strategic partnership to explore new mRNA vaccine tumor immunity solutions
April 14, 2025
Source: drugdu
44
On April 9, according to the official microblog of CanSino Biologics, CanSino Biologics (Shanghai) Co., Ltd., a subsidiary of CanSino Biologics, and Tianjin Jiankai Technology Co., Ltd. (hereinafter referred to as "Jiankai Technology"), a wholly-owned subsidiary of Jiankai Technology, recently signed a cooperative development agreement. The two parties will jointly promote the clinical research project of mRNA vaccines for the treatment of glioblastoma (GBM), and it is expected that the first patient will be dosed this year.
https://finance.eastmoney.com/a/202504093371737123.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Weixinkang’s wholly-owned subsidiary obtains approval for clinical trial of succinylated gelatin injection April 18, 2025
- The first treatment guideline for Asian pancreatic cancer patients was released, and therapeutic vaccines also officially entered the clinic April 17, 2025
- The first influenza vaccine bidding this year was announced, and each shot costs only 10 yuan April 17, 2025
- Obtained Korean Drug Registration Certificate April 17, 2025
- China’s first AAV gene therapy breaks through April 17, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
